Floatz logo

Bxcl501

Dexmedetomidine

Peking University First HospitalPhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Dexmedetomidine cohort.

Asset / SponsorPhaseRating
S-Ketamine
Peking University First Hospital
Phase 4BB
Amitriptyline
Peking University First Hospital
Phase 4BB
Pregabalin
Peking University First Hospital
Phase 4BB
SUFENTANYL
Peking University First Hospital
Phase 4BB
Zofran
Peking University First Hospital
Phase 4BB

View all 21 →

Same molecule, other indications

Bxcl501 is also rated in:

Pain, ChronicDormant
A
Indicative ·
80 / 100
View asset →
Agitation,PsychomotorDormant
A
Indicative ·
80 / 100
View asset →
schizophreniform disorderDormant
A
Indicative ·
80 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →